The most powerful cholesterol-lowering medicines available, blocking a liver protein to cut harmful cholesterol far below older drugs. In people with existing heart and artery disease, they clearly reduce heart attacks, strokes, procedures, and can shrink artery plaque, with mild injection reactions the only consistent downside. Effects on lifespan and early low-risk use stay unproven. (Full Review)

Protocol

Positioning

Add-on to statin

Added when LDL or apolipoprotein B stays above target on a maximally tolerated statin with or without ezetimibe; used earlier in statin-intolerant patients and familial hypercholesterolemia

Agent & Dosing

Subcutaneous injection

Evolocumab 140 mg every 2 weeks or 420 mg monthly; alirocumab 75–150 mg every 2 weeks; inclisiran 284 mg at day 1, month 3, then every 6 months

Strategy

Conventional vs. lower-and-earlier

Reserve for the highest-risk, highest-LDL patients, or target apolipoprotein B well below conventional thresholds; both presented as legitimate

Time to effect

LDL Reduction

1–2 weeks

Near-maximal effect by 4–8 weeks

Event Reduction

Months to years

Accrues and grows with continued use

Heart Attack & Stroke

Second year onward

Reduction strengthens as plaque stabilizes

Benefits

High: Dramatic LDL cholesterol reduction, reduced major adverse cardiovascular events, reduced heart attack and ischemic stroke, coronary plaque regression

Medium: Lipoprotein(a) lowering, reduced coronary revascularization, cardiovascular mortality benefit (conflicted), peripheral artery disease and limb-event reduction

Low: Reduced venous thromboembolism risk

Speculative: Slowed aortic valve stenosis progression, extension of healthy lifespan, LDL-independent anti-inflammatory effects

Contraindications

Known serious hypersensitivity to the agent or its excipients

Pregnancy and breastfeeding (avoid unless clearly needed)

Key Interactions

Additive LDL lowering with statins and ezetimibe

Additive LDL-lowering supplements and agents (red yeast rice, plant sterols/stanols, soluble fiber, berberine, bempedoic acid)

Inclisiran combined with a monoclonal antibody not standard

Lipoprotein apheresis (frequency may be reduced under specialist care)

Risk & Side Effects

High: Injection-site reactions

Medium: Flu-like symptoms and nasopharyngitis, hypersensitivity and allergic reactions

Low: New-onset diabetes (conflicted), neurocognitive effects (conflicted), immunogenicity, hemorrhagic stroke

Speculative: Long-term effects of ultra-low LDL cholesterol

Monitoring

Marker	Target	Why
LDL cholesterol (LDL-C)	<70 mg/dL for high risk; many longevity clinicians target <55 or <40 mg/dL	Primary target of therapy
Apolipoprotein B (apoB)	<60 mg/dL (many target <50)	Counts atherogenic particles; better risk marker than LDL-C alone
Lipoprotein(a) [Lp(a)]	<30 mg/dL (<75 nmol/L)	Independent genetic risk factor lowered by antibodies
Non-HDL cholesterol	<80 mg/dL for high risk	Captures all atherogenic cholesterol; useful when triglycerides are high
hs-CRP	<1.0 mg/L	Marker of vascular inflammation and residual risk
Fasting glucose / HbA1c	Glucose <100 mg/dL; HbA1c <5.7%	Screens for the small theoretical diabetes signal
ALT / AST	Within normal laboratory limits	General hepatic safety context (mainly for co-administered statin)

Cadence: Lipid panel and apolipoprotein B at 4–8 weeks after starting or any dose change, then every 6–12 months once stable; glucose periodically (e.g., annually) in at-risk patients

Qualitative Assessment

Adherence and injection tolerability
Overall energy and exercise capacity
Confidence and stress around cardiovascular risk

PCSK9 Inhibitors for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment